Successful Treatment of MMP-9-Expressing Angiosarcoma with Low-Dose Docetaxel and Bisphosphonate

Case Rep Dermatol. 2012 Jan;4(1):5-9. doi: 10.1159/000335999. Epub 2012 Jan 11.

Abstract

We describe a 78-year-old Japanese patient with angiosarcoma on the scalp. Interestingly, immunohistochemical staining revealed this tumor as positive for matrix metalloproteinase 9 (MMP-9). After conventional therapy for angiosarcoma with surgical treatment and radiation therapy, we intravenously administered docetaxel at 40 mg/m(2) body surface area together with oral administration of 17.5 mg sodium risedronate hydrate. One and a half years after the standard treatment, there was no evidence of local recurrence or metastasis.

Keywords: Angiosarcoma; Bisphosphonate; Docetaxel; MMP-9.

Publication types

  • Case Reports